Discussion & Conclusion
Due to the known difficulties to isolate native human neuromelanin, synthetic DA-melanin is commonly used as a model of the natural pigment. Several studies indicate that DA-melanin may affect the process of lipid peroxidation. It has been found that DA-melanin inhibited Fe(II)- or Fe(II)/ascorbate- initiated lipid peroxidation in lecithin and cardiolipin liposomes, and in methyl linoleate aqueous dispersion [29,30,38]. Furthermore, the ability of this melanin to suppress lipid peroxidation induced by UV-light or a water-soluble radical initiator has been demonstrated [30,39]. On the other hand, DA-melanin has been shown to potentiate lipid peroxidation in rat cerebral cortex homogenates after addition of iron [32].
In the presented study, melanin prepared by copolymerization of DA and CysDA, and "pure" phaeomelanin obtained from CysDA were used, in addition to DA-melanin, as models of neuromelanins. DA/CysDA-melanin appears to be the most adequate model of neuromelanin. Degradative studies described by Odh et al. [13] indicate that the pigment of human substantia nigra is a mixed-type melanin and consists of units derived from benzothiazines and from indoles in about equal amounts (the content of phaeomelanin units was in the range 32-60% in different individuals). These authors have also demonstrated that for synthetic melanins formed from CysDA and DA, the sulfur content multiplied by nine gave an estimate of the percentage of benzothiazine-derived units in the polymer. Based on this finding and on sulfur content determined by elemental analysis we estimated the percentage of phaeomelanin units in DA/CysDA-melanin preparation to be about 56%.
The effect of model neuromelanins obtained from CysDA and from DA/CysDA-mixture on Fe(II)/ascorbate-induced lipid peroxidation in linoleic acid micelles and in lecithin liposomes was investigated and compared to the effect of DA-melanin. The results of this study demonstrated that all melanins tested significantly suppressed peroxidation of both linoleic acid and liposomal lecithin in a concentration dependent manner. The inhibitory effect of DA/CysDA-melanin was similar to that of DA-melanin in both lipid systems. This indicates that incorporation of phaeomelanin component into eumelanin polymer does not affect essentially its antioxidant activity. Instead, CysDA-melanin was shown to be less effective inhibitor of lecithin peroxidation than DA-melanin.
Recently, we demonstrated that DA-melanin was capable of reducing linoleic acid hydroperoxide to its more stable hydroxyl derivative, both in the absence and in the presence of ferrous ions [31]. The results of the present study indicate that DA/CysDA-melanin and CysDA-melanin also posses the abilities to reduce the fatty acid hydroperoxide. The effectiveness of CysDA-melanin in conversion of 13-HPODE to 13-HODE was lower than DA-melanin and DA/CysDA-melanin. The reductive inactivation of lipid hydroperoxides is known to prevent hydroperoxide-dependent secondary lipid peroxidation. Our results suggest that the model neuromelanins can act as "chain-breaking" antioxidants.
It is known, that DA-melanin, like other eumelanins, has iron-chelating capability [32,33]. Melanin-bound ferric ions are catalytically inactive and may be released from the complex only by strong reductants. There is some evidence that antioxidant action of DA-melanin is due to its ability to sequester redox-active iron ions [30,33]. Nevertheless, lipid chains are prevented from peroxidative damages as long as melanin capacity to bind iron ions is not exhausted. Zareba et al. [33] have demonstrated that DA-melanin saturated with ferric ions could enhance the formation of free hydroxyl radicals by redox activation of the ions, and postulated that under conditions, that stimulate the release of bound iron, melanin acts as an efficient prooxidant. Such prooxidant effect was observed in our experiments only when the lowest concentrations of DA/CysDA-melanin and CysDA-melanin were investigated.
Our studies have proved that mixed-type melanin formed by copolymerization of dopamine and 5-S-cysteinydopamine, and phaeomelanin originated from cysteinyldopamine are able to inhibit the process of lipid peroxidation induced by ferrous ions in the presence of ascorbic acid. Antioxidant efficiences of DA/CysDA-melanin and DA-melanin were similar, and some higher than of CysDA-melanin. The results obtained strongly suggest, that under physiological conditions neuromelanin can act as natural antioxidant. The fatty acid hydroperoxide-reducing ability demonstrated for the model neuromelanins appears to be involved in the mechanism of antioxidative activity of neuromelanin.
References
1.Rodgers, AD and Curzon, G (1975) Melanin formation by human brain in vitro. Journal of Neurochemistry, 24:1123-1129.
2.Graham, DG (1978) Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Molecular Pharmacology, 14:633-643.
3.Marsden, CD (1983) Neuromelanin and Parkinson's disease. Journal of Neural Transmission, Supplementum, 19:121-141.
4.Carstam, R; Brinck, C; Hindemith-Augustsson, A; Rorsman, H and Rosengren, E (1991) The neuromelanin of the human substantia nigra. Biochimica et Biophysica Acta, 1097:152-160.
5.Tse, DCS; McCreery, RL and Adams, RN (1976) Potential oxidative pathways of brain catecholamines. Journal of Medicinal Chemistry, 19:37-40.
6.Ito, S; Fujita, K; Yoshioka, M; Sienko, D and Nagatsu,T (1986) Identyfication of 5-S- and 2-S-cysteinyldopamine and 5-S-glutathionyldopamine formed from dopamine by high-performance liquid chromatography with electrochemical detection. Journal of Chromatography, 375:134-140.
7.Shen, XM and Dryhurst,G (1996) Further insights into the influence of L-cysteine on the oxidation chemistry of dopamine: reaction pathways of potential relevance to Parkinson's disease. Chemical Research in Toxicology, 9:751-763.
8.Zhang, F and Dryhurst, G (1994) Effects of L-cysteine on the oxidation chemistry of dopamine: new reaction pathways of potential relevance to idiopathic Parkinson's disease. Journal of Medicinal Chemistry, 37:1084-109
9.Zhang, F and Dryhurst,G. (1995) Reactions of cysteine and cysteinyl derivatives with dopamine-o-quinone and further insights into the oxidation chemistry of 5-S-cysteinyldopamine: potential relevance to idiopathic Parkinson's disease. Chemical Research in Toxicology, 9:751-763.
10.Rosengren, E; Linder-Eliasson, E and Carlsson, A (1985) Detection of 5-S-cysteinyldopamine in human brain. Journal of Neural Transmission, 63:247-253.
11.Fornstedt ,B; Brun, A; Rosengren, E and Carlsson, A (1989) The apparent autoxidation rate of catechols in dopamine-rich regions of human brains increases with the degree of depigmentation of substantia nigra. Journal of Neural Transmission, 1:279-295.
12.Cheng, FC; Kuo, JS; Chia, LG and Dryhurst, G (1996) Elevated 5-S-cysteinyldopamine/homovanillic acid ratio and reduced homovanilic acid in cerebrospinal fluid: possible markers for and potential insights into the pathoetiology of Parkinson's disease. Journal of Neural Transmission, 103:433-446.
13.Odh, G; Carstam, R; Paulson, J; Wittbjer, A; Rosengren, E and Rorsman, H (1994) Neuromelanin of the human substantia nigra: a mixed- type melanin. Journal of Neurochemistry, 62:2030-2036.
14.Miller, RT; Lau, SS and Monks, TJ (1995) Metabolism of 5-(glutathion-S-yl)-alfa-methyldopamine following intracerebroventricular administration to male Sprague-Dawley rats. Chemical Research in Toxicology, 8:634-641.
15.Okun, MR (1997) The role of peroxidase in neuromelanin synthesis: a review. Physiological Chemistry and Physics & Medical NMR, 29:15-22.
16.Rabey, JM and Hefti, F (1990) Neuromelanin synthesis in rat and human substantia nigra. Journal of Neural Transmission, 2:1-14.
17.Rosei, MA; Blarzino, C; Foppoli, C; Mosca, L and Coccia, R (1994) Lipoxygenase-catalyzed oxidation of catecholamines. Biochemical and Biophysical Research Communications, 200:344-350.
18.Hastings, TG (1995) Enzymatic oxidation of dopamine: the role of prostaglandin H synthetase. Journal of Neurochemistry, 64:919-924.
19.Mattammal, MB; Strong, R; Lakshuri, VM; Chung, HD and Stephenson, AH (1995) Prostaglandin H synthetase-mediated metabolism of dopamine: implication for Parkinson's disease. Journal of Neurochemistry, 64:1645-1654.
20.Enochs, WS; Sarna, T; Zecca, L; Riley, PA and Swartz, HM (1994) The roles of neuromelanin, binding of metal ions, and oxidative cytotoxicity in the pathogenesis of Parkinson's disease: a hypothesis. Journal of Neural Transmission, 7:83-100.
21.Graham, DG (1979) On the origin and significance of neuromelanin. Archives of Pathololgy and. Laboratory Medicine. 103:359-362.
22.Smythies, J (1996) On the function of neuromelanin. Proceedings of the Royal. Society London. B, 263:487-489.
23.Hirsch, E; Graybiel, AM and Agid, YA (1988) Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Nature, 334:345-348.
24.Kastner, A; Hirsch, EC; Lejeune, O; Javoy-Agid, F; Rascol, O and Agid, Y (1992) Is the vulnerability of neurons in the substantia nigra of patients with Parkinson's disease related to their neuromelanin content? Journal of Neurochemistry, 59:1080-1089.
25.Dexter, DT; Carter, CJ; Wells FR; Javoy-Agid, F; Agid, Y; Lees, AJ; Jenner, P and Marsden, CD (1989) Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. Journal of Neurochemistry, 52:381-389.
26.Jenner, P; Dexter, DT; Sian, J; Schapira, AHV and Marsden, CD (1992) Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental Lewy body disease. Annals of Neurology, 32:S82-S87.
27.Fahn, S and Cohen, G (1992) The oxidant stress hypothesis in Parkinson's disease: evidence supporting it. Annals of Neurology, 32:804-812.
28.D'Ischia, M and Prota, G (1997) Biosynthesis, structure, and function of neuromelanin and its relation to Parkinson's disease: a critical update. Pigment Cell Research, 10:370-376.
29.Porebska-Budny, M; Sakina,NL; Stepien, KB; Dontsov, AE and Wilczok, T (1992) Antioxidative activity of synthetic melanins. Cardiolipin liposome model. Biochimica et Biophysica Acta, 1116:11-16.
30.Korytowski, W; Sarna, T and Zareba, M (1995) Antioxidant action of neuromelanin: the mechanism of inhibitory effect on lipid peroxidation. Archives of Biochemistry and Biophysics, 319:142-148.
31.Stepien, K; Zajdel, A; Swierczek, G; Wilczok, A and Wilczok,T (1998) Reduction of 13-hydroperoxy-9,11-octadecadienoic acid by dopamine-melanin. Biochemical and Biophysical Research Communications, 244:781-784.
32.Ben-Shachar,D; Riederer, P and Youdim, MBH (1991) Iron-melanin interaction and lipid peroxidation: implications for Parkinson's disease. Journal of Neurochemistry, 57:1609-1614.
33.Zareba, M; Bober, A; Korytowski, W; Zecca, L and Sarna, T (1995) The effect of a synthetic neuromelanin on yield of free hydroxyl radicals generated in model systems. Biochimica et Biophysica Acta, 1271:343-348.
34.Zecca, L; Shima, T; Stroppolo, A; Goj, C; Battiston, GA; Gerbasi, R; Sarna, T and Swartz, HM (1996) Interaction of neuromelanin and iron in substantia nigra and other areas of human brain. Neuroscience, 73:407-415.
35.Bangham, AD; Hill, MW and Miller, NGA (1974) Preparation and use of liposomes as models of biological membranes. In:Methods in Membrane Biology (ed. Korn, ED), Plenum Press, New York-London, 1:1-68.
36.Buege, J and Aust, SD (1978) Microsomal lipid peroxidation. Methods in Enzymology, 52C:302-310.
37.Gibian,M and Vandenberg, P (1987) Product yield in oxygenation of linoleate by soybean lipoxygenase: the value of the molar extinction coefficient in the spectrophotometric assay. Analytical Biochemistry, 163:343-349.
38.Stepien, K and Wilczok, T (1994) Antioxidant activity of model neuromelanins in the process of lipid peroxidation. Current Topics in Biophysics, 18:135-138.
39.Stepien, K; Porebska-Budny, M; Hollek, AM and Wilczok, T (1992) The inhibiting effect of catecholamine-melanins on UV-induced lecithin peroxidation. Journal of Photochemistry and Photobiology.B:Biology, 15:223-231.